

# David Gracie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2211114/publications.pdf>

Version: 2024-02-01

73  
papers

2,320  
citations

361045

20  
h-index

223531

46  
g-index

73  
all docs

73  
docs citations

73  
times ranked

2702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14256.	1.6	6
2	Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1773-1780.	6.1	61
3	Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. <i>Gastroenterology</i> , 2022, 163, 190-203.e5.	0.6	17
4	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1976-1987.	6.1	69
5	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1738-1739.	2.4	0
6	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. <i>Gut</i> , 2021, 70, 218.2-219.	6.1	12
7	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gut</i> , 2021, 70, 1110-1116.	6.1	49
8	Mood and Treatment Persistence in Inflammatory Bowel Disease: Time to Consider Integrated Models of Care?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1111-1113.	2.4	2
9	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. <i>Gastroenterology</i> , 2021, 160, 466-467.	0.6	0
10	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. <i>Gastroenterology</i> , 2021, 160, 2611-2613.	0.6	3
11	Longitudinal follow-up study: effect of psychological comorbidity on the prognosis of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 441-450.	1.9	19
12	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 132-139.	0.8	1
13	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. <i>Neurogastroenterology and Motility</i> , 2021, , e14282.	1.6	1
14	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1000-1001.	2.4	1
15	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1053-1062.	3.7	109
16	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 632-642.	3.7	186
17	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 572-573.	2.4	1
18	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13666.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. <i>Gastroenterology</i> , 2019, 156, 2345-2347.	0.6	2
20	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231983843.	1.1	11
21	Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. <i>Gastroenterology</i> , 2019, 157, 1429-1430.	0.6	0
22	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. <i>American Journal of Gastroenterology</i> , 2018, 113, 773-774.	0.2	1
23	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774473.	1.4	18
24	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 700-707.	0.6	35
25	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1597-1605.	0.9	20
26	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 702-712.	0.2	65
27	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 1635-1646.e3.	0.6	258
28	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1165-1167.	2.4	16
29	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13174.	1.6	37
30	Reply. <i>Gastroenterology</i> , 2018, 155, 1652-1653.	0.6	0
31	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	21
32	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 376-384.e5.	2.4	87
33	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 824-832.	1.9	10
34	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 189-199.	3.7	212
35	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 762-763.	1.9	4
36	Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1268-1269.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1315-1316.	2.4	0
38	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1638.	2.4	2
39	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 324-325.	0.6	14
40	Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?. <i>Gastroenterology</i> , 2017, 153, 1451-1452.	0.6	3
41	Editorial: probiotics in inflammatory bowel disease—wrong organisms, wrong disease, or flawed concepts? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 633-634.	1.9	0
42	Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 461-462.	1.9	1
43	Ongoing Symptoms in Ulcerative Colitis Patients in Remission. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E4-E5.	0.9	6
44	Amoebic colitis. <i>Diagnostic Histopathology</i> , 2017, 23, 563-565.	0.2	4
45	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. <i>Gastroenterology</i> , 2017, 153, 1444-1445.	0.6	6
46	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 389-400.	1.9	285
47	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 63-74.	1.9	36
48	The possible risks of proton pump inhibitors. <i>Medical Journal of Australia</i> , 2016, 205, 292-293.	0.8	9
49	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 549-561.	1.9	136
50	Editorial: Using Patient-Reported Outcome Measures in Gastroenterology: PROMISed Land or Road to Nowhere?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1557-1558.	0.2	2
51	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 541-551.	0.2	117
52	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. <i>Gastroenterology</i> , 2016, 151, 762-763.	0.6	2
53	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.2	41
54	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 440-440.	1.9	1

#	ARTICLE	IF	CITATIONS
55	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1246-1246.	1.9	0
56	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1198.	0.2	8
57	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 117-126.	1.9	56
58	Response to Levenstein and Prantera. <i>American Journal of Gastroenterology</i> , 2016, 111, 1499.	0.2	0
59	Letter: deleterious effects of smoking on postoperative Crohn's disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1248-1248.	1.9	0
60	Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders – brain-gut, gut-brain, or both?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 899-900.	1.9	1
61	Validation and modification of a diagnostic scoring system to predict microscopic colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1206-1212.	0.6	16
62	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. <i>American Journal of Gastroenterology</i> , 2016, 111, 900-901.	0.2	1
63	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1061-1062.	2.4	5
64	Symbiotics in irritable bowel syndrome – better than probiotics alone?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 485-489.	1.3	6
65	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1024-1031.	1.6	18
66	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 491-503.	1.9	69
67	IBS-like symptoms in patients with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 101.	1.0	31
68	Defining the Relationship Between Clinical and Biochemical Disease Activity Indices and Perceived Stress in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1632-1634.	0.6	2
69	Letter: is there a bi-directional relationship between depression and IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 213-213.	1.9	2
70	Functional Bowel Symptoms in Quiescent Inflammatory Bowel Disease: More Than Just Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2014, 147, 1176-1177.	0.6	5
71	Limited Evidence for the Existence of Postdiverticulitis Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1521.	2.4	0
72	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 983.	1.6	84

#	ARTICLE	IF	CITATIONS
73	Evidence-based management of ulcerative colitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2012, 58, 87-99.	2.2	6